Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis

2011 ◽  
Vol 38 (9) ◽  
pp. 1925-1930 ◽  
Author(s):  
MURRAY BARON ◽  
MARIE HUDSON ◽  
RUSSELL STEELE ◽  
ERNEST LO ◽  
Keyword(s):  
Clinical Trial ◽  
Systemic Sclerosis ◽  
Gastrointestinal Tract ◽  
Los Angeles ◽  
Formal Education ◽  
Short Form ◽  
Health Assessment ◽  
Original Cohort ◽  
Gi Symptoms ◽  
Version 2.0

Objective.The University of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium GI Tract Instrument (UCLA SCTC GITI) was recently developed to measure gastrointestinal tract disease in systemic sclerosis (SSc). Our study assesses the internal consistency and validity of the instrument in a different population than was used in the original study.Methods.A sample of 113 consecutive patients with SSc from the Canadian Scleroderma Research Group (CSRG) Registry completed the UCLA SCTC GITI, a self-administered questionnaire with 7 scales and an overall score. Reliability was evaluated using Cronbach’s alpha coefficient and validity was determined by testing multiple constructs.Results.Our subjects were slightly older than the original cohort, and had less formal education and less diffuse cutaneous disease. The overall score of the instrument correlated well with the GI scale of the Health Assessment Questionnaire for the Spondyloarthropathies (GI-S-HAQ; r = 0.58, p < 0.001) and the total number of GI symptoms (r = 0.77, p < 0.001). Each subscale correlated well with the GI-S-HAQ. The individual scales and the overall score were able to differentiate between categorical groupings of the GI-S-HAQ. The scale scores differentiated well those patients with clinical involvement of the corresponding GI problem. Multiple linear regression adjusting for age, disease duration, sex, and ethnicity showed that the UCLA SCTC GITI had a significant association with both the physical component summary and the mental component summary of the Medical Outcomes Study Short-Form 36 questionnaire.Conclusion.Our study confirms that the UCLA SCTC GITI version 2.0 will be a useful tool for assessing the role of GI involvement in SSc, even in a population with substantially different characteristics than the subjects originally tested.

UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Reflux Scale correlates with impaired Esophageal Scintigraphy findings in Systemic Sclerosis

2021 ◽  
pp. jrheum.201283
Author(s):  
Giuseppina Abignano ◽  
Gianna Angela Mennillo ◽  
Giovanni Lettieri ◽  
Duygu Temiz Karadag ◽  
Antonio Carriero ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Systemic Sclerosis ◽  
Gastrointestinal Tract ◽  
Los Angeles ◽  
Esophageal Transit ◽  
Gi Symptoms ◽  
Esophageal Scintigraphy ◽  
Patient Reported ◽  
Esophageal Transit Scintigraphy ◽  
Esophageal Emptying

Objective The University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA GIT 2.0) questionnaire is a self-reported tool measuring gastrointestinal (GI) quality of life in systemic sclerosis (SSc) patients. Scarce data are available on the correlation between patient reported GI symptoms and motility dysfunction as assessed by esophageal transit scintigraphy. Methods We evaluated the UCLA GIT 2.0 reflux scale in SSc patients admitted to our clinic and undergoing esophageal transit scintigraphy, and correlated their findings. Results Thirty-one SSc patients undergoing esophageal transit scintigraphy were included. Twentyseven were female, 8 with diffuse cutaneous subset; 26/31 (84%) patients had a delayed transit and an abnormal esophageal emptying activity. Mean (SD) emptying activity percentage was higher in patients with none-to-mild GIT 2.0 reflux score [81.1 (11.5)] than in those with the moderate [55.7 (17.8), p = 0.003] and severe-to-very-severe scores [55.8 (19.7), p = 0.002]. The 26 (84%) SSc patients with delayed esophageal transit had a higher GIT 2.0 reflux score (p=0.04). Percentage of esophageal emptying activity negatively correlated with the GIT 2.0 reflux score (r = - 0.68, p < 0.0001) while it did not correlate with the other scales and the total GIT 2.0 score. Conclusion SSc patients with impaired esophageal scintigraphy findings have a higher GIT 2.0 reflux score. The UCLA SCTC GIT 2.0 is a complementary tool for objective measurement of esophageal involvement which can be easily administered in day-to-day clinical assessment.

scholarly journals Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument

2009 ◽  
Vol 61 (9) ◽  
pp. 1257-1263 ◽  
Author(s):  
Dinesh Khanna ◽  
Ron D. Hays ◽  
Paul Maranian ◽  
James R. Seibold ◽  
Ann Impens ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Gastrointestinal Tract ◽  
Los Angeles ◽  
Reliability And Validity ◽  
University Of California ◽  
The University

scholarly journals Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Tracy Frech ◽  
Kirsten Novak ◽  
Monica P. Revelo ◽  
Maureen Murtaugh ◽  
Boaz Markewitz ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Gastrointestinal Tract ◽  
Los Angeles ◽  
Low Dose ◽  
Treatment Options ◽  
Case Series ◽  
Common Symptom ◽  
Naltrexone Hydrochloride ◽  
The University ◽  
Low Dose Naltrexone

Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this case series we report three patients that had significant improvement in pruritus and total GIT symptoms as measured by the 10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an effective, highly tolerable, and inexpensive treatment for pruritus and GIT symptoms in SSc.

scholarly journals Evaluation of quality of life, functionality and disability in patients with systemic sclerosis in a University Hospital

2020 ◽  
Vol 45 ◽  
pp. e020025
Author(s):  
Amanda Maria da Silva ◽  
Letticia Cristina Santos Cardozo Roque ◽  
Rafaela Silva Guimarães Gonçalves ◽  
Angela Luzia Branco Pinto Duarte ◽  
Angélica da Silva Tenório ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systemic Sclerosis ◽  
Short Form ◽  
Hand Function ◽  
Health Assessment ◽  
University Hospital ◽  
High Morbidity ◽  
Cross Sectional ◽  
Convenience Sample

Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by progressive fibrosis of the skin and internal organs that promotes high morbidity and mortality. Objective: To evaluate the functionality, disability and quality of life of patients with systemic sclerosis and to compare the clinical forms of the disease. Methods: Cross-sectional, descriptive and analytical study performed at the Rheumatology Clinic of the Hospital das Clínicas of the Federal University of Pernambuco (HC-UFPE) from August 2018 to April 2019. The non-probabilistic, convenience sample consisted of 60 patients diagnosed with systemic sclerosis (SSc), followed at the Rheumatology outpatient clinic of the Hospital das Clínicas, Federal University of Pernambuco. To evaluate the outcomes, the following instruments were used: Cochin Hand Functional Scale (CHFS) for hand function; 12-Item Short-Form Health Survey (SF-12) for quality of life; and Scleroderma Health Assessment Questionnaire (SHAQ) for functionality and disability. Results: The mean results for CHFS, SHAQ, SF-12 Physical Component Summary and SF-12 Mental Component Summary were 14.5 (6.0-29.75), 1.01±0.56, 35.04±8.09, 40.94±10.56, respectively. There were no significant differences in CHFS outcomes between patients with diffuse and limited forms of SSc, SHAQ and the mental component of SF-12. However, in the physical component of SF-12, a better score was found in patients with the diffuse form of the disease (p=0.04). Conclusion: Patients with SSc present an important impairment of hand function, quality of life and functional capacity, and those with limited cutaneous form present worse scores of the physical component in the evaluation of quality of life.

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

2008 ◽  
Vol 69 (01) ◽  
pp. 193-197 ◽  
Author(s):  
V Smith ◽  
J T Van Praet ◽  
B Vandooren ◽  
B Van der Cruyssen ◽  
J-M Naeyaert ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Short Form ◽  
Health Assessment ◽  
Histopathological Study ◽  
Open Label ◽  
Serious Adverse Events ◽  
Open Label Study ◽  
Skin Sclerosis ◽  
Potential Efficacy ◽  
Diffuse Cutaneous Systemic Sclerosis

Objectives:The safety and potential efficacy of rituximab was examined in diffuse cutaneous systemic sclerosis (dc-SSc).Methods:A 24 week open-label study in which eight patients with dc-SSc received an infusion of 1000 mg rituximab administered at baseline and day 15, together with 100 mg methylprednisolone at each infusion. Assessment included CD19+ peripheral blood lymphocyte number, skin sclerosis score, indices of internal organ functioning, the health assessment questionnaire disability index, the 36-item Short Form health survey and histopathological evaluation of the skin.Results:Ritixumab induced effective B-cell depletion in all patients (<5 CD19+ cells/μl blood). There was a significant change in skin score at week 24 (p<0.001). Also, significant improvements were measured in the dermal hyalinised collagen content (p = 0.014) and dermal myofibroblast numbers (p = 0.011). Two serious adverse events occurred, which were thought to be unrelated to the rituximab treatment.Conclusions:Rituximab appears to be well tolerated and may have potential efficacy for skin disease in dc-SSc.This study is registered with ClinicalTrials.gov, number NCT00379431.

Sign in / Sign up

Export Citation Format

Share Document